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Aim: Chemotherapy-induced toxicity is an independent prognostic indicator in several
cancers. We aimed to determine whether toxicity was related to survival and histological
response in high-grade localised extremity osteosarcoma. We undertook a retrospective
analysis of patients treated within three consecutive randomised controlled trials (RCTs)
of the European Osteosarcoma Intergroup.
Methods: Between 1982 and 2002, 533 patients were randomised to six cycles of doxorubicin
75 mg/m2 and cisplatin 100 mg/m2. Toxicity data were collected prospectively and graded
according to the World Health Organisation (WHO) criteria. Standard univariate and multi-
variate models were constructed to examine the relationship between reported toxicity,
survival, and histological response.
Results: Five- and 10-year overall survival was 57% (95% confidence interval (CI) 52–61%)
and 53% (49–58%), respectively. Grades 3–4 oral mucositis (hazard ratio (HR) 0.51, 95% CI
0.29–0.91), grades 1–2 nausea/vomiting (HR 0.37, 95% CI 0.16–0.85), grades 1–2 thrombocyto-
penia (HR 0.49, 95% CI 0.27–0.87), good histological response (HR 0.42, 95% CI 0.27–0.65), and
distal tumour site (HR 0.45, 95% CI 0.28–0.71) were associated with improved survival in
multivariate analysis. The only factors that were independently associated with histologi-
cal response were older age (odds ratio (OR) 0.18, 95% CI 0.04–0.72) and chondroblastic
tumour (OR 0.28, 95% CI 0.10–0.77), both being associated with a significantly lower chance
of achieving a good response.d by Elsevier Ltd.
t of Oncology, University College Hospital, 250 Euston Road, London NW1 2PG, UK.
.uk (J.S. Whelan).
Intergroup.
Open access under CC BY license. 
704 E U R O P E A N J O U R N A L O F C A N C E R 4 8 ( 2 0 1 2 ) 7 0 3 –7 1 2Conclusion: Chemotherapy-induced toxicity predicts survival in patients with localised
extremity osteosarcoma. Investigation of the pharmacogenomic mechanisms of constitu-
tional chemosensitivity underlying these observations will present opportunities for per-
sonalising treatment and could lead to improved outcomes.
Crown Copyright  2011 Published by Elsevier Ltd. Open access under CC BY license. 1. Introduction
Osteosarcoma is the commonest primary bone sarcoma
affecting young people. The prognosis of patients with high-
grade localised extremity osteosarcoma improved dramati-
cally with the introduction of multi-disciplinary treatment
(surgical resection in conjunction with perioperative multi-
agent chemotherapy) but over the past two decades there
have been no further improvements in survival.
Histological response to pre-operative chemotherapy is
strongly related to the outcome, with patients who achieve
a good histological response having a better prognosis than
those who do not.1–4 However, identifying other factors that
are reliably prognostic for survival or predictive of response
to treatment has been problematic and, although evidence
for the influence of several other factors, including histologi-
cal subtype,5 has been reported, none routinely influence
practice.
In other cancers, chemotherapy-induced toxicity has been
shown to be an independent prognostic indicator, with those
patients who report greater toxicity also having improved sur-
vival. The strongest association has been with myelosuppres-
sion. Prognostic effects of chemotherapy-induced
neutropenia have been demonstrated in breast,7 gastric,6
lung7,8 and ovarian cancer9 in adults; and in children and ado-
lescents receiving maintenance treatment for acute lympho-
blastic leukaemia.10,11 Chemotherapy-induced lymphopenia
has been shown to be prognostic in advanced breast cancer,
soft-tissue sarcoma, and diffuse large B-cell lymphoma.12 If a
similar association between toxicity and either histological re-
sponse or survival was found in patients with osteosarcoma,
an understanding of the underlying genetic and other mecha-
nismswhichmay explain this constitutional chemosensitivity
could lead to the testing and development of therapeutic strat-
egies toexploit orcircumvent thesephenomena,with thepros-
pect of greater individualisation of treatment and improved
outcomes.
The European Osteosarcoma Intergroup (EOI) has com-
pleted three randomised controlled trials (RCTs), involving
over 1000 patients with localised extremity osteosarcoma.
The same ‘standard’ treatment arm was used in all three, cre-
ating a uniquely large cohort treated in a standard manner
and followed prospectively.
To explore whether chemotherapy-induced toxicity was
associated with outcome in patients with high-grade osteo-
sarcoma, we undertook a retrospective analysis exploring fac-
tors relating to survival and histological response in this
cohort.2. Patients and methods
2.1. Patients
Between 1982 and 2002, three consecutive EOI chemotherapy
RCTs (MRC BO02/EORTC80831, BO03/80861, BO06/80931) ran-
domised 1067 patients. In each, one arm of the randomisation
was a ‘standard’ treatment: six 3-weekly cycles of doxorubi-
cin 25 mg/m2/d for 3 d, plus cisplatin 100 mg/m2 as a contin-
uous 24-h infusion on day 1. Hydration schedules were
protocol-specified but other supportive care, including antie-
metic regimens, was in accordance with the local practice at
trial sites. Surgery was scheduled after either three (BO02
and BO03) or two (BO06) cycles. Full details of each trial are re-
ported elsewhere.4,13,14 Ninety-nine patients were random-
ised to standard treatment in BO02 (1983–1986),13 199 in
BO03 (1986–1991),4 and 245 in BO06 (1993–2002).14 Ten patients
electively treated with post-operative chemotherapy alone in
BO02 were excluded from this study, in line with previous re-
ports from this series.5,13,15 In total, 533 patients were in-
cluded in the current combined analysis (Fig. 1).
Patients aged 640 years with histologically proven, high-
grade, localised extremity osteosarcoma, and adequate renal
and cardiac function were eligible. Patients who had received
prior chemotherapy or had a previous malignancy were inel-
igible. Ethics approval was granted at all institutions, and
written informed consent obtained from the patient or par-
ent, in accordance with the local regulatory guidelines. Pa-
tients were randomised within 35 d after diagnostic biopsy.
The resected specimen was examined histologically to assess
response to pre-operative chemotherapy. Good histological
response was defined as P90% necrosis in the tumour re-
sected. Both the diagnostic pathology and response assess-
ment were reviewed by the EOI pathology sub-committee.
2.2. Data
In each RCT, toxicity data were collected prospectively at each
cycle of chemotherapy using standardised case-report forms
and graded at site according to the World Health Organisation
(WHO) criteria16 for haematological toxicity, infection, muco-
sitis, nausea/vomiting, neurological toxicity and cardiac tox-
icity. Renal toxicity was not specifically recorded in BO06 so
this factor was not included in this combined analysis. The
worst grade of toxicity for each patient in any pre-operative
cycle was used in analyses of histological response, and the
worst grade of toxicity per-patient for all cycles was used in
the analyses of overall and progression-free survival. Data
Fig. 1 – CONSORT diagram.
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the first trial (BO02). Data on non-haematological toxicity
were available for 517/533 (97%) patients. Data on histological
response were available for 351/533 (66%) patients.
2.3. Statistical analysis
This was a retrospective analysis, carried out on an intention-
to-treat basis, in which data from the original three trials
were combined and analysed as one data-set. Analyses were
undertaken to examine prognostic factors for overall survival,
progression-free survival (PFS) and histological response.
Baseline characteristics examined included: collaborative
group, geographical location, age, gender, primary site (bone
affected), proximal versus distal tumour (proximal defined
as a proximal tumour of the humerus or femur; distal as all
other sites), and histological subtype. Treatment-related fac-
tors included type and timeliness of surgery, histological re-
sponse to pre-operative chemotherapy and chemotherapy-
induced toxicity. A two-sided significance level of 5% was
adopted. Stata 9 (StataCorp, College Station, TX) was used
for the analysis.
Analyses of factors influencing overall survival and PFS
used standard time-to-event methodology (survival analy-
sis).17 Median follow-up was calculated by reverse censoring
on overall survival. Overall survival was timed until death(from any cause) or patients were censored at the date of
last follow-up if death had not occurred. PFS was timed until
date of first event (local or metastatic disease progression or
death but excluding apparent progression of local disease
before primary surgery), or censoring occurred at date of last
follow-up. Fourteen patients had apparent progression of lo-
cal disease before primary surgery but these events were not
included in recognition that early clinical distinction be-
tween response and progression is unreliable in osteosar-
coma; the patients were included in the survival analyses.
The relative risks of each factor are summarised using haz-
ard ratios (HR) from univariate and multivariate Cox regres-
sion models. HRs are expressed relative to patients in the
baseline category of the factor of interest; so an HR <1.0 indi-
cates a lower risk of the event compared to the baseline cat-
egory. Variables were considered to be nominal. For the
univariate models, survival was measured from date of ran-
domisation, or from date of surgery for factors measured at
surgery (histological response, type of surgery). In the multi-
variate analyses, survival was measured from the date of
surgery.
The impact of factors on histological response was exam-
ined using univariate and multivariate logistic regression
models, and expressed by odds ratios (OR). An OR >1.0 indi-
cates a greater chance of achieving a good response, com-
pared to the baseline category.
Table 1 – Patient demographics and clinical characteristics.
Total (n = 533)
Collaborative group
MRC 334 (63%)
EORTC 199 (37%)
Geographical location
UK/Ireland 303 (57%)
Mainland Europe 136 (26%)
Othersa 94(18%)
Age at randomisation
Median (years) 15 (12–19)
Min–Max 3–40
0–10 years 93 (17%)
11–15 years 181 (34%)
16–20 years 172 (32%)
21–25 years 52 (10%)
P26 years 35 (7%)
Missing 0 (n/a)
Sex
Male 323 (61%)
Female 207 (39%)
Missing 3 (n/a)
Site of tumour
Femur 307 (58%)
Tibia 136 (26%)
Fibula 28 (5%)
Humerus 52 (10%)
Radius 6 (1%)
Missing 4 (n/a)
Location of tumour
Proximalb 69 (13%)
Distalc 458 (87%)
Missing 6 (n/a)
Classification of sarcoma
Common-type 331 (66%)
Chondroblastic 55 (11%)
Fibroblastic 38 (8%)
Osteoclast rich 6 (1%)
Anaplastic 16 (3%)
Small cell 6 (1%)
Telangiectatic 26 (5%)
Other 22 (4%)
Missing 33 (n/a)
Trial
BO02/80831 89 (17%)
BO03/80931 199 (37%)
BO06/80861 245 (46%)
Data are number (%) or median (IQR).
a Other geographical location = South America, South Africa, Saudi
Arabia, Canada, New Zealand.
b Proximal = proximal humerus/femur.
c Distal = all other sites.
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tients with missing data for the variable of interest were
excluded from that particular univariate analysis. Only pa-
tients with data available for all factors were incorporated
in the multivariate analyses. All models were stratified by
trial.3. Results
3.1. Patient characteristics
Patient characteristics are shown in Table 1. They were
broadly similar across all three studies, although the propor-
tion of males and chondroblastic osteosarcomas was lower
in BO02 (Supplementary data). Median age was 15 years (Inter
Quartile Range (IQR), 12–19). Median follow-up was 9.9 years
(5.2–14.8); being 17.9 years (16.8–19.2) for BO02; 12.7 years
(11.1–14.7) for BO03; and 5.0 years (3.0–7.0) for BO06.
3.2. Treatment
Treatment received is shown in Table 2. The proportion of pa-
tients completing six cycles of chemotherapy as scheduled
was 80%. Six percent of patients stopped treatment due to
progressive disease. Patients were slightly more likely to be
reported as stopping early for excessive toxicity within BO02
(Supplementary Data). Most toxicities were common with
>90% of patients reporting nausea/vomiting (504/519) and leu-
copenia (409/437); and >60% reporting mucositis (338/518),
infection (321/517) and thrombocytopenia (342/427).
Patients were more likely to undergo an amputation in
BO02 (44%) compared to the later studies (26% within each)
(Supplementary data). The overall proportion of patients
achieving a good histological response was 35%.
3.3. Overall survival
The 5- and 10-year overall survival for all patients was 57%
(95% confidence interval (CI) 52–61%) and 53% (49–58%),
respectively (Fig. 2). In total, 227 deaths were observed.
Univariate and multivariate analyses for overall survival
are shown in Table 3.
3.3.1. Factors at diagnosis
No differences in survival were observed according to collab-
orative group, geographical location, or age. Female gender
was associated with improved survival in univariate analysis,
but the effect size decreased in the multivariate model. Pri-
mary site was a prognostic indicator, with the humerus hav-
ing the poorest survival (5-year overall survival 41%, 95% CI
27–55%), and the tibia the best (66%, 57–73%). Patients with
proximal tumours had poorer survival compared to those
with distal tumours (40%, 28–52% versus 60%, 55–64%). There
was no statistically significant difference in survival between
themain histological subtypes but the small (n = 22) heteroge-
neous group categorised as ‘other’ appeared to have the poor-
est prognosis.
3.3.2. Treatment-related factors
Histological response was prognostic for survival, with pa-
tients who had a good histological response having a 5-year
overall survival of 71% (95% CI 61–78%) versus 47% (38–51%)
for those with a poor response. There was no evidence of a
difference in survival according to the type of surgery or for
patients whose surgery took place more than 10 d later than
specified. In univariate analysis, early surgery was associated
with worse 5-year survival, being 42% (24–59%), versus 55%
Table 2 – Treatment details, response and toxicity.
Total (n = 533)
Reason off-study
Treatment completed 423 (80%)
Disease progression 29 (6%)
Excessive toxicity 35 (7%)
Treatment refusal 16 (3%)
Other 25 (5%)
Missing 5 (n/a)
Type of surgery
Amputation 147 (29%)
Limb salvage 359 (71%)
Missing 25 (n/a)
Histological response
Poor 228 (65%)
Good 123 (35%)
Missing 182 (n/a)
Max oral mucositis grade
Grade 0 180 (35%)
Grades 1–2 223 (43%)
Grades 3–4 115 (22%)
Missing 15 (n/a)
Max nausea/vomiting grade
Grade 0 15 (3%)
Grades 1–2 182 (35%)
Grades 3–4 322 (62%)
Missing 14 (n/a)
Max cardiac gradea
Grade 0 464 (90%)
Grades 1–2 48 (9%)
Grades 3–4 6 (1%)
Missing 15 (n/a)
Max infection grade
Grade 0 196 (38%)
Grades 1–2 201 (39%)
Grades 3–4 120 (23%)
Missing 16 (n/a)
Max neurological grade
Grade 0 458 (89%)
Grades 1–2 58 (11%)
Grades 3–4 1 (0%)
Missing 16 (n/a)
Max leucopenia grade
Grade 0 28 (6%)
Grades 1–2 66 (15%)
Grades 3–4 343 (79%)
Missing 96 (n/a)
Max thrombocytopenia grade
Grade 0 95 (22%)
Grades 1–2 114 (26%)
Grades 3–4 228 (52%)
Missing 96 (n/a)
Data are number (%).
a As recorded during chemotherapy only.
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95% CI 0.98–2.87) but this effect disappeared in multivariate
analysis (0.91, 0.28–3.01).
Chemotherapy-induced toxicities were prognostic for
overall survival, with the presence of greater toxicity gener-ally being associated with better survival. In univariate anal-
ysis, toxicities with the greatest effect on survival were
grades 3–4 oral mucositis (Fig. 3), grades 1–2 peripheral neu-
ropathy and thrombocytopenia of any grade (Fig. 3). Grades
1–4 nausea/vomiting identified a group of patients with some
evidence of improved survival (Fig. 3). Within multivariate
analysis, grades 3–4 oral mucositis, grades 1–2 nausea/vomit-
ing and grades 1–2 thrombocytopenia were associated with
improved survival. No evidence of an association with sur-
vival was found with leucopenia, infection or cardiac toxicity
(experienced during chemotherapy). Only one patient experi-
enced grades 3–4 peripheral neuropathy so no results could
be drawn for this category. Stratifying by whether or not pa-
tients had completed all six cycles of chemotherapy had no
impact on the toxicity-related factors that were statistically
significant for an impact on survival (data not shown).
3.4. Progression-free survival
Five- and 10-year PFS was 44% (95% CI 40–49%) and 44%
(39–48%), respectively (Fig. 2), with 284 events observed. The
univariate and multivariate analyses for PFS are shown in Ta-
ble 3. Primary site and histological response to pre-operative
chemotherapy were also strongly associated with PFS but
there was no evidence of an association with gender or time-
liness of surgery. Within multivariate analysis, patients with
anaplastic tumours (16/328) appeared to have a better PFS
compared to other histological subtypes. Chemotherapy-in-
duced toxicity was also a prognostic factor for PFS. Grades
1–4 oral mucositis, grades 1–2 nausea/vomiting, grades 1–2
peripheral neuropathy, thrombocytopenia of any grade and
grades 3–4 leucopenia were associated with improved PFS in
univariate analysis; on multivariate analysis, the effect of leu-
copenia and grades 1–2 oral mucositis lessened.3.5. Histological response
Older age and chondroblastic tumours were associated with a
significantly lower chance of reporting a good histological re-
sponse (age P26 years, OR 0.18, 95% CI 0.04–0.72; chondrob-
lastic tumours, 0.28, 0.10–0.77) (Supplementary data). No
association was found with chemotherapy-induced toxicity,
or any other factor.4. Discussion
This paper uniquely explores the association between chemo-
therapy-induced toxicity and outcome in patients with osteo-
sarcoma. Chemotherapy-induced toxicity was associated
with improved overall and progression-free survival. It did
not predict an increased likelihood of having a good histolog-
ical response to pre-operative chemotherapy, however,
although this was itself prognostic for survival. Although
the results are derived from a cohort of patients treated with
doxorubicin and cisplatin alone, these agents remain central
to all widely used regimens for osteosarcoma. The incorpora-
tion of other agents such as methotrexate into current regi-
mens may alter the spectrum of toxicities experienced by
patients and, while there is no empirical reason to conclude
At risk:
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Fig. 2 – Overall and progression-free survival.
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value of chemotherapy-induced toxicity, further study is
warranted.
In studies exploring chemotherapy-induced toxicity in
other cancers, myelosuppression has been associated with
improved outcome raising the possibility of using this as an
indicative marker for chemotherapy efficacy.6,12,18 In contrast,
we found that non-haematological toxicities appear to be a
better indicator of survival in osteosarcoma. Although there
was a trend for improved survival in patients experiencing
myelosuppression, this only remained statistically significant
for thrombocytopenia. It is likely that patients with osteosar-
coma experience a higher incidence of grades 3–4 myelosup-
pression than patients with other tumours, due to more
aggressive chemotherapy, thus diminishing its relative asso-
ciation with survival. In addition, although not routinely re-
corded in these trials, G-CSF was permitted on a per-patient
basis, which may have reduced the overall incidence of neu-
tropenia. Increased nausea and vomiting was associated with
a trend for increased survival. The reported incidence of this
toxicity decreased in later studies, probably due to better anti-
emetic prophylaxis; hence it is likely that its prognostic sensi-
tivity has now decreased.
In osteosarcoma, little is known about the influence of in-
ter-patient variations in chemotherapy metabolism on its tol-
erability or effectiveness. Wide inter- and intra-variability in
serum methotrexate levels has been observed following
high-dose methotrexate (8–12 g/m2).19 Higher serum metho-
trexate levels have been linkedwith better survival20,21 but re-
sults have been inconsistent, with others finding no
difference or even poorer survival, with peak concentrations
>1500 lM.22 There are no systematic studies on pharmacoge-
netic markers linked to cisplatin or doxorubicin metabolism.
However, studies to identify relevant polymorphisms in pa-
tients with osteosarcoma are now underway.23
This analysis has some limitations. Haematological toxicity
data were not available for the earliest trial and histologicalresponse to chemotherapy was missing for 182 patients
(34%). Despite this being, for osteosarcoma, a large cohort,
someof the categories in the analyses involved small numbers,
inparticular: histological subtypesother thancommon-typeor
chondroblastic, and grades 3–4 neurological and cardiac toxic-
ity. Thesewere retrospective exploratory analyseswhich are at
risk of statistical anomalies. Additionally, other factors of po-
tential interestwerenot routinely recorded, including lympho-
cyte count, alkaline phosphatase and lactate dehydrogenase
levels, nephrotoxicity and tumour size. Only acute cardiac tox-
icity was recorded and it remains possible that sub-acute or
late cardiac toxicitymay be associatedwith survival. Although
the toxicity data was recorded using a standardised grading
system, there is a subjective element to assessing non-haema-
tological toxicity and we could not control for variation be-
tween individual investigators. Early lymphocyte recovery
following chemotherapy has been suggested to be prognostic
in a small study of children with osteosarcoma,24 with similar
findings reported in Ewing’s sarcoma,25 and this observation
warrants investigation in future prospective studies.
Although the main chemotherapy protocol remained con-
stant, other aspects of osteosarcoma treatment and support-
ive care changed over the 20 years that these studies cover. In
the later RCTs, limb-sparing surgery was performed more of-
ten and the use of more effective antiemetics has already
been cited as a probable reason for a decrease in the reported
incidence of chemotherapy-induced nausea and vomiting.
Changes in practice are accounted for by the modelling tech-
niques used in this analysis; however, other changes are more
problematic. For example, the decreased prevalence of com-
mon-type osteosarcoma and increased proportion of chond-
roblastic tumours over time may be due to improvements in
pathology. Such changes in reporting practices are not always
easily identifiable, and are difficult to account for in retro-
spective analyses.
These data for osteosarcoma are consistent with those
from other cancers in showing that the presence of some
Table 3 – Univariate and multivariate Cox models for overall and progression-free survival.
n Overall survival Progression-free survival
Univariate models Multivariate model (n = 328) Univariate models Multivariate model (n = 328)
Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
Year of randomisationa
Each additional
year from 1983
533 1.01 (0.98–1.03) 0.599 1.02 (1.00–1.04) 0.052
Collaborative group 533
MRC 1.00 1.00 1.00 1.00
EORTC 1.03 (0.78–1.35) 0.856 0.53 (0.19–1.45) 0.217 0.92 (0.72–1.18) 0.529 0.50 (0.21–1.18) 0.112
Geographical location 533
UK/Ireland 1.00 1.00 1.00 1.00
Mainland Europe 1.09 (0.79–1.49) 0.599 1.44 (0.49–4.24) 0.510 0.91 (0.68–1.22) 0.536 1.48 (0.57–3.89) 0.422
Other 1.02 (0.70–1.49) 0.905 1.23 (0.52–2.94) 0.638 0.93 (0.67–1.29) 0.673 1.16 (0.55–2.41) 0.697
Age group 533
610 years 1.00 1.00 1.00
11–15 years 1.07 (0.72–1.61) 0.730 1.08 (0.64–1.83) 0.777 1.20 (0.85–1.71) 0.305 1.30 (0.83–2.05) 0.254
16–20 years 1.17 (0.78–1.75) 0.448 1.27 (0.74–2.18) 0.382 1.14 (0.80–1.64) 0.471 1.24 (0.76–2.02) 0.381
21–25 years 0.92 (0.53–1.61) 0.772 0.75 (0.34–1.64) 0.467 0.92 (0.56–1.51) 0.748 0.87 (0.45–1.69) 0.676
P26 years 1.53 (0.87–2.67) 0.136 2.03 (0.97–4.24) 0.061 1.22 (0.72–2.06) 0.468 1.29 (0.61–2.69) 0.505
Gender 530
Male 1.00 1.00 1.00 1.00
Female 0.73 (0.55–0.97) 0.028 0.68 (0.45–1.01) 0.054 0.82 (0.64–1.04) 0.101 0.80 (0.57–1.12) 0.189
Site of tumoura 529
Femur 1.00 1.00
Tibia 0.68 (0.49–0.96) 0.026 0.69 (0.51–0.93) 0.014
Fibula 0.94 (0.52–1.70) 0.842 0.92 (0.54–1.56) 0.749
Humerus 1.57 (1.07–2.32) 0.023 1.81 (1.27–2.57) 0.001
Other 0.53 (0.13–2.14) 0.371 0.66 (0.21–2.06) 0.471
Location of tumour 527
Proximal 1.00 1.00 1.00 1.00
Distal 0.54 (0.39–0.75) <0.001 0.45 (0.28–0.71) 0.001 0.49 (0.36–0.66) <0.001 0.34 (0.23–0.52) <0.001
Type of osteosarcoma 500
Common-type 1.00 1.00 1.00 1.00
Chondroblastic 1.13 (0.73–1.74) 0.575 0.75 (0.42–1.36) 0.343 1.38 (0.96–1.99) 0.081 0.87 (0.54–1.40) 0.575
Fibroblastic 1.16 (0.72–1.89) 0.545 1.49 (0.78–2.86) 0.226 1.11 (0.71–1.76) 0.643 1.61 (0.88–2.95) 0.119
Anaplastic 0.84 (0.37–1.91) 0.682 0.39 (0.12–1.34) 0.137 0.74 (0.35–1.58) 0.435 0.32 (0.11–0.95) 0.040
Telangiectatic 1.23 (0.64–2.38) 0.530 0.98 (0.45–2.17) 0.967 0.84 (0.45–1.57) 0.590 0.77 (0.37–1.63) 0.500
Other 1.77 (1.08–2.90) 0.023 1.88 (1.01–3.50) 0.046 1.64 (1.05–2.57) 0.029 1.38 (0.78–2.42) 0.265
Oral Mucositis 518
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.75 (0.57–1.00) 0.053 1.01 (0.67–1.53) 0.946 0.70 (0.53–0.90) 0.007 0.96 (0.66–1.38) 0.809
Grades 3–4 0.38 (0.25–0.57) <0.001 0.51 (0.29–0.91) 0.023 0.48 (0.34–0.68) <0.001 0.61 (0.37–0.99) 0.046
(continued on next page)
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Table 3 – Continued
n Overall survival Progression-free survival
Univariate models Multivariate model (n = 328) Univariate models Multivariate model (n = 328)
Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
Nausea and vomiting 519
Grade 0 1.00 1.00
Grades 1–2 0.60 (0.31–1.16) 0.129 0.37 (0.16–0.85) 0.020 0.55 (0.30–1.00) 0.049 0.35 (0.16–0.76) 0.008
Grades 3–4 0.60 (0.31–1.14) 0.117 0.53 (0.23–1.20) 0.127 0.61 (0.34–1.10) 0.103 0.49 (0.22–1.05) 0.068
Infection 517
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.84 (0.62–1.14) 0.269 0.91 (0.58–1.42) 0.666 0.90 (0.68–1.19) 0.459 1.07 (0.72–1.60) 0.733
Grades 3–4 0.71 (0.49–1.03) 0.072 0.90 (0.52–1.56) 0.715 0.85 (0.62 –1.17) 0.313 1.44 (0.89–2.32) 0.135
Cardiac 518
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.84 (0.52–1.36) 0.481 0.85 (0.44–1.68) 0.648 0.99 (0.66–1.49) 0.959 1.44 (0.83–2.48) 0.193
Grades 3–4 0.71 (0.18–2.90) 0.636 1.02 (0.13–8.07) 0.988 0.67 (0.21–2.12) 0.501 1.04 (0.23–4.65) 0.958
Neurological 517
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.51 (0.31–0.85) 0.010 0.81 (0.43–1.52) 0.513 0.45 (0.28–0.72) 0.001 0.56 (0.32–0.99) 0.044
Grades 3–4 1.73 (0.24–12.42) 0.587 0.71 (0.07–7.63) 0.780 3.75 (0.52–27.22) 0.192 2.16 (0.21–22.72) 0.520
Leucopenia 437
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.88 (0.48–1.62) 0.678 0.86 (0.35–2.12) 0.741 0.76 (0.44–1.30) 0.309 0.67 (0.31–1.44) 0.304
Grades 3–4 0.60 (0.35–1.03) 0.063 0.82 (0.33–2.00) 0.662 0.56 (0.35–0.89) 0.014 0.66 (0.31–1.38) 0.267
Thrombocytopenia 437
Grade 0 1.00 1.00 1.00 1.00
Grades 1–2 0.56 (0.37–0.84) 0.005 0.49 (0.27–0.87) 0.016 0.58 (0.41–0.83) 0.003 0.50 (0.30–0.83) 0.008
Grades 3–4 0.59 (0.42–0.83) 0.003 0.63 (0.36–1.13) 0.119 0.59 (0.43–0.80) 0.001 0.58 (0.35–0.96) 0.035
Histological responseb 351
Poor 1.00 1.00 1.00 1.00
Good 0.42 (0.28–0.62) <0.001 0.42 (0.27–0.65) <0.001 0.38 (0.27–0.54) <0.001 0.36 (0.25–0.54) <0.001
Surgery typeb 506
Amputation 1.00 1.00 1.00 1.00
Limb salvage 0.80 (0.59–1.07) 0.130 0.81 (0.51–1.28) 0.367 0.84 (0.65–1.10) 0.214 0.84 (0.55–1.27) 0.407
Timeliness of surgeryb 505
On-time 1.00 1.00 1.00 1.00
Early 1.67 (0.98–2.87) 0.060 0.91 (0.28–3.01) 0.878 1.61 (0.96–2.70) 0.070 0.77 (0.25–2.41) 0.654
Late 0.89 (0.67–1.18) 0.416 0.97 (0.67–1.41) 0.886 1.00 (0.78–1.29) 0.981 1.01 (0.73–1.40) 0.972
Models stratified by trial (except for year of randomisation in univariate models). Toxicity grade = maximum recorded over all cycles for each category. Location of tumour: proximal = proximal
humerus/femur; distal = all other sites. Surgery type: amputation includes rotationplasty and disarticulation. Timeliness of surgery: on-time = between 3 d earlier and 10 d later than specified in
protocol; early = more than 3 d earlier than specified; late = more than 10 d later than specified.
a Not included in multivariate model due to overlap with other variables.
b Timed from date of surgery (includes multivariate model).
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Fig. 3 – Overall survival, according to chemotherapy related
toxicity.
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vival. Doxorubicin and cisplatin remain an integral part of
treatment together with high-dose methotrexate in the cur-
rent EURAMOS-1 trial (NCT00134030).26 A similar association
between toxicity and survival may exist with this regimen
and can be explored when the trial matures. In the absenceof new chemotherapy agents, novel approaches to optimising
treatment are still needed and the prospect of individualisa-
tion of treatment through isotoxic regimens is an intriguing
prospect that could be explored in future clinical trials. How-
ever, this is complicated by our finding that non-haematolog-
ical, rather than haematological, toxicity was the strongest
predictor of survival. Due to the subjective elements of evalu-
ating non-haematological toxicity, and the effects of improve-
ments in supportive care, further elucidation of the
underlying mechanisms which account for individual varia-
tion in toxicity and how these might link to mechanisms of
tumour sensitivity and resistance are necessary before reli-
able recommendations can be made. For now, lack of toxicity
may provide early evidence of reduced constitutional chemo-
sensitivity, and predict poorer outcome in patients with
osteosarcoma.
Osteosarcoma predominantly affects adolescents and
young adults (AYAs) and age-group specific differences in
pharmacodynamics have been postulated to be one of the
reasons that survival in AYAs with cancer has failed to im-
prove at the same rate as that of children and older adults.
There are few data directly addressing chemotherapy dosing
in this age-group. The next RCT from the EURAMOS group in-
tends to address these issues and to capture individual’s ge-
netic information. Our data encourage the search for
genetic predictors of individual toxicity and sensitivity to che-
motherapy in osteosarcoma.Funding
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